Letter to Editor Rheumatology: Commentaries and Controversies (LER) has been an online forum for a stronger voice and a wider audience for critical and dissenting views in rheumatology and related disciplines. It has joined forces with Clinical and Experimental Rheumatology to achieve the deserved wider audience.
Letters can be submitted solely to: https://www.clinexprheumatol.org, please read Authors’ Guidelines.
2013
Belimumab in the treatment of lupus: is the target really the group which is difficult to cure in daily practice?
O. Nuri Pamuk
Lett Ed Rheumatol 2013; 3 (1): e130001
Monotherapy for rheumatoid arthritis treatment?
Y. Yazici
Lett Ed Rheumatol 2013; 3 (2): e130002
2012
Treat to target (T2T) in rheumatoid arthritis – the con side
E. Ben-Chetrit
Lett Ed Rheumatol 2012; 2 (1): e120001
What should we do about criteria in rheumatology?
R.A. Luqmani, P.H. Plotz
Lett Ed Rheumatol 2012; 2 (1): e120002
Comments on the nonsteroidal antiinflammatory drug withdrawal in patients with stable rheumatoid arthritis
S. Ugurlu
Lett Ed Rheumatol 2012; 2 (1): e120003
Response to: Comments on the nonsteroidal antiinflammatory drug withdrawal in patients with stable rheumatoid arthritis
G.E. McKellar
Lett Ed Rheumatol 2012; 2 (1): e120004
Safe use of rituximab in a pregnant woman with Henoch-Schonlein purpura
R. Nayfe, A. Mehdi, Ghina Ghazeeri, I. Uthman
Lett Ed Rheumatol 2012; 2 (1): e120005
Comments on the risk of pulmonary embolism in Behçet's syndrome
S. Ugurlu, Y. Yazici, G. Hatemi, S. Yurdakul
Lett Ed Rheumatol 2012; 2 (2): e120006
Comment on the clinical efficacy and safety of Etanercept versus sulfasalazine in patients with ankylosing spondylitis (the ASCEND trial)
S. Akar, S. Yurdakul
Lett Ed Rheumatol 2012; 2 (2): e120007
2011
Differences in levels of disease activity in rheumatoid arthritis patients from different countries
Y. Yazici, H. Yazici, T. Pincus
Lett Ed Rheumatol 2011; 1 (1): e110001
In randomized trials, statistical tests are not helpful to study prognostic (im)balance at baseline
M. Boers
Lett Ed Rheumatol 2011; 1 (1): e110002
Comments on the sensitivity and specificity of a new molecular test for Mycobacterium tuberculosis and resistence to rifampin
G. Hatemi
Lett Ed Rheumatol 2011; 1 (1): e110003
Response to: Comments on the sensitivity and specificity of a new molecular test for Mycobacterium tuberculosis and resistence to Rifampin
C.C. Boehme
Lett Ed Rheumatol 2011; 1 (1): e110004
Is PET/CT an alternative to conventional cancer screening in dermatomyositis/polymyositis?
J. Bourré-Tessier, H.A. Ménard
Lett Ed Rheumatol 2011; 1 (1): e110005
Is there really a higher risk for infection with anti TNF-α agents or is there a selection bias?
S. Yurdakul
Lett Ed Rheumatol 2011; 1 (1): e110006
A critical review of the American College of Rheumatology/European League Against Rheumatism criteria for the classification of rheumatoid arthritis
I. Simsek, Y. Yazici
Lett Ed Rheumatol 2011; 1 (1): e110007
Comments on the diagnostic role of ultrasonography in patients with gout
M. Korkmaz, I. Gunaydin
Lett Ed Rheumatol 2011; 1 (1): e110008
Rhabdomyolysis as the presenting symptom of lung carcinoma: a case report
D. Buyuktas, K. Tascilar, S. Ugurlu, H. Unalan, H. Ozdogan
Lett Ed Rheumatol 2011; 1 (2): e110009
Allopurinol in renal insufficiency: a reappraisal
A.M. Abeles, M.H. Pillinger
Lett Ed Rheumatol 2011; 1 (2): e110010
Effective Consumer Scale (EC-17) for use in trials of patient empowerment, patient education or self management
A. Lyddiatt, T. Rader, P. Tugwell
Lett Ed Rheumatol 2011; 1 (2): e110011